Nemaura Medical to Present at the Maxim Group 2022 Virtual Growth Conference

Rhea-AI Summary

Nemaura Medical, Inc. (NASDAQ: NMRD), a leader in wearable diagnostic devices, announces that CEO Dr. Faz Chowdhury will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. A corporate overview will be presented on March 28 at 9:00 a.m. ET, accessible to registered investors. The company is commercializing innovative products like sugarBEAT®, a continuous glucose monitor aimed at diabetes management, and proBEAT™, an AI-enhanced health service. Nemaura also launched Miboko, focusing on metabolic health, targeting a market projected to exceed $59 billion by 2025.

Loughborough, England, March 24, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held on March 28-30, 2022.

Dr. Chowdhury will present a corporate overview which will become available on Monday, March 28, 2022 at 9:00 a.m. ET.

Investors can view the presentation by registering for the conference here and also request a one-on-one meeting with management to be arranged following the conclusion of the conference.

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

When will Nemaura Medical's CEO present at the conference?

Dr. Faz Chowdhury will present on March 28, 2022, at 9:00 a.m. ET.

What is the focus of Nemaura Medical's products?

Nemaura Medical specializes in wearable diagnostic devices for diabetes management and metabolic health.

What is sugarBEAT® and its significance?

sugarBEAT® is a CE mark approved continuous glucose monitor designed to help manage diabetes.

How can investors view the presentation from Nemaura Medical?

Investors can register for the Maxim Group conference to view the presentation.

What markets is Nemaura Medical targeting?

Nemaura targets the Type 2 diabetes market, projected to reach nearly $59 billion by 2025.